The Ca 2+ /calmodulin complex interacts with and regulates various enzymes and target proteins known as calmodulin-binding proteins (CaMBPs). This group of proteins includes molecular motors such as myosins. In this study, we show that non-muscle myosin-IIB is overexpressed in the brains of diabetic rats. We isolated CaMBPs from the brains of non-diabetic rats and rats with streptozotocin-induced diabetes and purified them by immobilized-calmodulin affinity chromatography. The proteins were eluted with EGTA and urea, separated by SDS-PAGE, digested and submitted to peptide mass fingerprinting analysis. Thirteen intense bands were found in both types of brains, two were found exclusively in non-diabetic brains and four were found exclusively in diabetic brains. A large fraction of the eluted proteins contained putative IQ motifs or calmodulin-binding sites. The results of the myosin-IIB affinity chromatography elution, western blot and RT-PCR analyses suggest that myosin-IIB protein and mRNA are expressed at high levels in diabetic brains. This is the first study that has demonstrated differential expression of CaMBPs in diabetic and non-diabetic brain tissue through a comparative proteomic analysis, and it opens up a new approach to studying the relationship between the expression of myosins in the brain, hyperglycemia and intracellular calcium regulation.
Introduction
Diabetes mellitus is a common metabolic disorder characterized by hyperglycemia that affects the central nervous system, causing alterations in neurotransmission, electrophysiological abnormalities, structural changes and moderate disturbances in learning and memory [1] [2] [3] [4] [5] . Hyperglycemia causes an acute rise in cytosolic calcium concentrations due to increased calcium influx into cells. In certain cells, hyperglycemia causes the release of intracellular calcium stores as well. Hyperglycemia has also been associated with decreased calcium efflux [6] . The combination of increased calcium influx and decreased calcium efflux leads to a sustained elevation of the basal level of cytosolic calcium that may adversely affect cell functions, including Ca 2+ -binding proteins such as calmodulin and its target proteins, which are capable of decoding very small changes in the intracellular concentration of calcium [7] .
Calmodulin is an ubiquitous, highly conserved acidic Ca 2+ -binding protein [8] . Binding of Ca 2+ releases Mg 2+ from calmodulin and causes the protein to undergo a conformational change that increases its binding affinity for a number of target proteins. Because Ca 2+ binds to calmodulin, a small change in the level of cytosolic calcium leads to a large change in the level of active proteins such as Ca 2+ /calmodulinbinding proteins [9, 10] .
Calmodulin-binding proteins can be classified into three categories based on their calcium ion dependence: Ca 2+ -dependent, Ca 2+ -independent and Ca 2+ -inhibited [8, 9] . Calmodulin binds to the target proteins via an IQ motif in a Ca 2+ -independent manner [11] , as has been observed for the light chains of different myosin classes [12] .
Myosins constitute a large family of actin-based motor proteins [13] that contains more than 18 classes and multiple members. Myosin classes I, II, V, VI, and IX are clearly present in vertebrate neurons. Isoforms of myosin-II are expressed in most non-muscle cells and exhibit differences in their biological properties, tissue distribution and intracellular localization, indicating that each isoform might perform different cellular functions [14, 15] . Myosin-IIB is important for growth cone motility and axon outgrowth [16] . Total or partial ablation of myosin-IIB can lead to damage to the nervous system as a result of a defect in migration [17] . Furthermore, a recent study showed that myosin-IIB is a necessary component of hippocampusdependent memory formation and synaptic plasticity in the mature nervous system [18] .
In the present investigation, we identified calmodulin-binding proteins in non-diabetic and diabetic rat brains and investigated the expression of non-muscle myosin heavy chain IIB in diabetic rat brains.
Material and methods

Animals
Male Wistar rats (180-220 g) were housed under standard conditions (22 ± 1°C, humidity 60± 5%, 12-h light/12-h dark cycle) with food and water ad libitum. All procedures for the handling, use and euthanasia of animals followed the resolutions proposed by the Brazilian Society of Science in Laboratory Animals and by the Ethics Committee in Animal Research of the Federal University of Uberlândia, Brazil.
Induction of diabetes mellitus
Rats were starved for 24-h, anesthetized by intraperitoneal injection of xylazine/ketamine (1:1 v/v), and injected with streptozotocin (40 mg/kg body weight, 0.01 M citrate buffer, pH 4.5; SigmaAldrich) via the penile vein (2 mL/kg). Fasting continued for 90 min after the injection. Ten days after injection with streptozotocin, rats with fasting blood glucose levels above 200 mg/dL were scored as diabetic. Glycemic levels were monitored for the subsequent 10 days with Biocheck Glucose Test Strips (Bioeasy). Animals were sacrificed by decapitation 20 days after the induction of diabetes and brains from both diabetic (n = 16) and non-diabetic (n = 16) rats were surgically removed.
Affinity chromatography
Calmodulin-coupled Sepharose-4B resin affinity chromatography (CaM-Sepharose-4B, Amersham Pharmacia Biotech) was carried out as previously described [19] . The resin was loaded into a glass column (10 × 0.5 cm) and equilibrated with 10 volumes of equilibration buffer (50 mM Tris-HCl, pH 7.5, 2 mM CaCl 2 , 1 mM β-mercaptoethanol) containing 100 mM NaCl. For each sample, four brains of the same type were homogenized on ice in three volumes of homogenization buffer (50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM β-mercaptoethanol, 1 mM benzamidine, 0.2 mM phenylmethane sulfonyl-fluoride (PMSF), 0.1 mM aprotinin, 20 μg/mL leupeptin, 0.1 mM pefabloc). The homogenate was centrifuged at 15,000 ×g for 30 min at 4°C. Supernatants were prepared for CaM-Sepharose-4B affinity chromatography by adding 2 mM CaCl 2 . Following application to the column, the excluded volume was discarded and the resin was washed with 10 volumes of equilibration buffer containing 200 mM NaCl, followed by 10 volumes of the same buffer containing 500 mM NaCl. CaMBPs were eluted with buffer containing 50 mM Tris-HCl (pH 7.5), 2 mM EGTA, 1 mM β-mercaptoethanol, 100 mM NaCl and 0.2 mM PMSF, followed by elution with buffer containing 50 mM Tris-HCl (pH 7.5), 6 M urea, 1 mM β-mercaptoethanol and 0.2 mM PMSF. Affinity chromatography was performed without specific protection of phosphate/phosphatases, and purification was carried out in triplicate. The protein content of the loaded supernatants and eluted fractions was estimated following a modification of the Bradford assay [20] and samples with protein concentrations below 2 μg/μL were treated with 10% trichloroacetic acid for 15 min on ice, and centrifuged at 12,000 ×g for 10 min at 4°C. The protein precipitate was then solubilized in a small volume of electrophoresis sample buffer containing an additional 100 mM Tris-HCl (pH 8.0) and 25% glycerol, analyzed on a 5-22% gradient SDS-PAGE [21] , and stained with Coomassie Brilliant Blue R-250.
Protein digestion and mass spectrometry
Prior to peptide mass fingerprinting analysis (PMF), the calmodulinbinding proteins of the eluted fractions were destained in the polyacrylamide gel. Tryptic digests were prepared on an AnchorChip™ plate (Bruker Daltonics) according to the modified method of Zhang et al. [22] . Mass spectra were obtained using an Autoflex II MALDI-TOF/TOF mass spectrometer (Bruker Daltonics) in delayed extraction and reflector modes. The spectra were processed using the FlexAnalysis 2.4 and BioTools 3.0 software tools (Bruker Daltonics). Peptide masses (MH + ) were recorded in the range of 700-3500 Da. Internal calibration was performed using known trypsin autolysis ion peaks (842.50 and 2211.09).
Database search
The monoisotopic masses of tryptic peptides were used to identify the proteins by peptide mass fingerprinting. Protein searches in the National Center for Biotechnology Information (NCBI) database were carried out using Mascot software [23] , assuming a p-value b 0.05. The error tolerance for peptide mass was lower than 100 ppm. No restrictions were imposed on protein molecular mass or phylogenetic lineage. Searches that provided no significant scores were then restricted to Rodentia. Further search parameters were the presence of one missed cleavage and the presence of sites for modifications, including methionine oxidation, cysteine carbamidomethylation and N-terminal acetylation (protein). Identified proteins were categorized via UniProt/TrEMBL. Those proteins that could not be categorized using this method were classified according to cellular localization using the Psort II database (http://psort.nibb.ac.jp/form2.html). A web-based database (http://calcium.uhnes.utoronto.ca/ctdb) was used to identify putative CaM-binding motifs within the primary sequence of the identified proteins; these motifs were classified as "potential IQ motif," "potential motif 1-5-10 subclass," "potential CaM-binding site," "nonspecific CaM-binding site" and "absent CaMbinding motif" [10, 24] .
Western blotting for myosin-IIB expression
Three diabetic and three non-diabetic brains (n = 3, respectively) were homogenized in homogenization buffer (50 mM Tris-HCl, pH 7.5, 10 mM EDTA, 2 mM EGTA, 5 mM ATP, 2 mM dithiothreitol, 1 mM benzamidine, 0.5 mM phenylmethane sulfonyl-fluoride, 0.1 M aprotinin, 20 μg/mL leupeptin, 0.1 mM pefabloc) and centrifuged at 15,000 ×g for 30 min at 4°C. The protein content of the supernatants was estimated using the Bradford assay. Supernatant samples containing 30 μg of protein were solubilized in a small volume of electrophoresis sample buffer containing an additional 100 mM Tris-HCl, pH 8.0, and 25% glycerol, analyzed by 5-22% SDS-PAGE and electroblotted on nitrocellulose membranes in Tris-glycine buffer [25] . The membranes were incubated with 5% dried milk in TBS-T (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween 20) and then probed with 0.2 μg/mL antimyosin-IIB primary antibody. Following washes with TBS-T, the blots were incubated with a peroxidase-conjugated anti-rabbit IgG (GE Healthcare; diluted 1:2000) and again washed several times with TBS-T. Antibodies bound to the membranes were visualized by chemiluminescence after treatment with ECL™ (GE Healthcare) followed by exposure to Hyperfilm™ (GE Healthcare) following manufacturer's instructions. The intensity of the protein bands was analyzed and compared using Scion Image software, version Alpha 4.0.3.2 (Scion Corporation) and results were expressed as percentage of total protein content.
RNA isolation and cDNA synthesis
Total RNA was isolated from four diabetic and four non-diabetic brains using TRIzol reagent (Invitrogen) following the manufacturer's instructions and then resuspended in DEPC-treated water. The quality and quantity of the isolated RNA were established by reading the optical density of each sample at 260 and 280 nm using NanoDrop® ND-1000 Spectrophotometer (Nanodrop Technologies) and agarose gel electrophoresis. One microgram of total RNA was reverse transcribed at 37°C for 1 h in a 20 μL reaction mixture containing the first strand buffer, 40 U Murine Monoley Leukemia Virus Reverse Transcriptase (Invitrogen), 0.25 mM of each dNTP, 10 U RNAsin (Invitrogen), 0.5 mM DTT, and 126 pmol hexamer random primers (Invitrogen).
Preparation of quantification standard
Standards were prepared by cloning PCR products of MYH10 and the housekeeping gene beta-2-microglobulin (B2M) fragments using TOPO TA Cloning Dual Promoter Kit (Invitrogen). The recombinant plasmid DNA was isolated and sequenced using MegaBACE 1000 automatic sequencer (Molecular Dynamics). The sequencing reaction was [26] . Serial dilutions of each standard were made in the range of 10 to 10 7 copies per μL for MYH10 and B2M.
The efficiency reaction was calculated according to the formula E = (10 − 1/slope − 1)× 100, where the log of each dilution was plotted against ΔC T of the housekeeping and target genes.
Real-time PCR conditions
The qPCR assay was carried out in a 7300 Real-time PCR System (PE Applied Biosystems) using SYBR Green qPCR Master Mix reagent (Fermentas). Thermal cycling was conducted using the Universal Program profile (PE Applied Biosystems). Primers were designed between exon junctions to avoid amplification of contaminating genomic DNA using Primers Express software (PE Applied Biosystems). The primers used for B2M fragment amplification were 5′-CGT CGT GCT TGC CAT TCA-3′ and 5′-TCC TCA ACT GCT ACG TGT CTC AG-3′. The MYH10 forward and reverse primers were 5′-CCA TGC CGG AGA ACA CAG T-3′ and 5′-AAG CCC AGA CCA AAG AGC AG-3′, respectively. The relative expression of each specific product was calculated by 2 −ΔΔCT (C T = fluorescence threshold value; ΔC T =C T of the target gene− C T of the reference gene (B2M); ΔΔC T = ΔC T of the target sample−ΔC T of the calibrator sample). All samples were run in duplicate.
Immunohistochemistry
Brains were dissected and fixed with 10% formaldehyde solution in 0.1 M phosphate-buffered saline (pH 7.4) for 24 h, dehydrated in ethanol, rinsed in xylene and embedded in paraffin. Five micrometer sections were pretreated with 4 mM citrate buffer (pH 6.0) containing 0.025% Tween 20 in a microwave for 5 min. The sections were then incubated with anti-myosin-IIB for 16 h followed by incubation with the Post Primary Block NovoLink™ Max Polymer Detection System (Novocastra Laboratories Ltd.). After three washes with TBS-T, the sections were incubated with the NovoLink polymer for 30 min at 37°C. Chromogen development was performed with 3,3′-diaminobenzidine, and the material was counterstained with Harris hematoxylin, dehydrated, mounted with Permount and analyzed using a light microscope (Zeiss Axiolab). Negative controls were prepared by omitting the primary antibody from the reaction.
Statistical analysis
Statistical analysis was performed with the Student t-test. The data were analyzed using SigmaStat 3.5 software (Systat Software Inc.). Means and standard deviations were calculated. A p-value b 0.05 was considered significant.
Results and discussion
In this study, we identified proteins from non-diabetic and diabetic rat brains that interact with the Ca 2+ /calmodulin complex. SDS-PAGE analysis of the EGTA-eluted fractions from a CaM-Sepharose-4B column revealed a similar protein profile for both types of brains, with fifteen intense bands for non-diabetic and sixteen for diabetic brains (Fig. 1) . The fraction eluted with 6 M urea revealed two proteins that were highly expressed in diabetic brains, myosin-IIB and cytoplasmic actin. Two calmodulin-binding proteins were found only in non-diabetic brains, four were exclusively identified in diabetic and thirteen were found in both types of rat brains ( Table 1) . The sequences of all identified proteins were analyzed for the presence of a calmodulin-binding motif using the database with respect to the presence of a calmodulin-binding motif. The proteins were classified as "potential IQ motif" (two), "potential motif 1-5-10 subclass" (two), "potential calmodulin-binding site" (eleven), "nonspecific calmodulin-binding motif" (two) and "absent calmodulin-binding motif" (one), as shown in Table 1 .
Two metabolic enzymes that are also well-known calmodulinbinding proteins were identified, phosphofructokinase and acyl CoA synthetase. Although phosphofructokinase was found in both types of brains, it has been reported that the levels of this enzyme are decreased in diabetic brains [27] . A number of cytoplasmic proteins were also identified in both the non-diabetic and diabetic brains: glycolipid transfer protein, a protein that accelerates the intermembrane transfer of various glycolipids [28] ; ubiquitin protein ligase E3C, which is thought to be the component of the ubiquitin conjugation system most directly responsible for substrate recognition [29, 30] and modulating the function of the synapse [31] ; and heat shock protein 8 (HSP70). Previous studies have shown that calmodulin binds to HSP70 in a calcium-dependent manner [32] and activates calcineurin via calmodulin-dependent and independent pathways [33] . Members of the HSP70 family often act as chaperones, regulating the folding and stability of several proteins, including receptors and signal transduction regulators, or as biomarkers of cellular death [34] .
Calmodulin is present in the nucleus of multiple cell types, suggesting that it is involved in the regulation of nuclear functions [9] . We detected three proteins predicted by Psort II to be localized to the nucleus: zinc finger protein 260, similar centromere protein F and microtubule-actin crosslinking factor 1. The identification of nuclear proteins was not unexpected because subcellular fractionation of biological samples is seldom complete [35] . Furthermore, all of these proteins interact with calmodulin and contain calmodulin-binding motifs.
Both the alpha and beta isoforms of Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) were identified. These common neural proteins mediate diverse physiological responses to increases in intracellular calcium concentrations by Ca 2+ /calmodulin complex activation in neurons [36] . The alpha and beta isoforms are neuron specific and highly abundant in rat brains [37] . CaMKII seems to be relatively vulnerable to pathological states that are associated with massive calcium influxes into cells [38] . The activity and enzyme content of CaMKII are increased in diabetic rat brains; this change may be a molecular cause of previously reported deficits in learning and hippocampal plasticity in diabetic subjects [38, 39] . There were four distinct bands of CaMKII that differed slightly in mass in both diabetic and non-diabetic brains, suggesting that the protein exists in different states of post-translational modifications such as phosphorylation, which is a key factor in the trafficking and functioning of this protein [40] . Several of the identified proteins, including actin, dynein, myosin, spectrin and tubulin, are implicated in cytoskeleton function. Modification of the actin expression pattern in diabetic brains may be related to structural changes driven by the reorganization of actin-microfilaments in the cell during the evolution of diabetes. Changes in neuronal activity can bring about rapid alteration of the size and morphology of these structures [41, 42] which in turn may change the synaptic efficacy; the dynamics of actin are particularly important in this process [43] . Another proteomic analysis of postsynaptic density identified many actin-regulatory proteins and an insulin receptor substrate protein that, when associated, increases the dynamics of actin [44] .
For the first time, we report overexpression of myosin-IIB in diabetic brain tissue. Although myosin-IIB lacks a calmodulin binding site, the light chain of this molecular motor interacts with and is regulated by a myosin light chain kinase that does have a calmodulinbinding site. Thus, myosin-IIB may have been co-purified with other calmodulin-binding molecules in our experiment.
Our analysis produced 61 peptides with m/z ratios ranging from 704.3800 to 2532.1070, in accordance with the predicted mass of in silico-digested non-muscle myosin heavy chain IIB (Fig. 2A) . The myosin-IIB identified in this search (accession number 13928704) has an estimated molecular mass of 229.79 kDa and an isoelectric point of 5.49 (Fig. 2B) . A Mascot search of the NCBI protein database revealed that these peptides covered 34% of the Rattus norvegicus myosin-IIB sequence (Fig. 2C) .
To evaluate the expressed protein concentration of myosin-IIB, western blot analysis was performed using supernatant from rat brain tissue. We observed an increase of about 59% in brain tissue of diabetic rats relative to that of non-diabetic rats (p b 0.05) (Fig. 3) . The differential expression of myosin-IIB protein in non-diabetic and diabetic brains originally observed by affinity chromatography, SDS-PAGE and western blotting was validated by real time PCR of MYH10 mRNA expression and by immunohistochemical analysis of the distribution of myosin-IIB protein.
Real-time PCR (Fig. 4 ) revealed that the MYH10 mRNA level was 1.4-fold higher in diabetic brain tissue (p b 0.001) than in non-diabetic, in agreement with the western blot. The amplification efficiency was tested using standard curves for Rattus norvegicus B2M (R 2 = 0.9997) and MYH10 (R 2 = 0.996) generated by plotting the value of the C T cycle vs. the log of plasmid concentration (from 10 4 to 10 6 copies). Linear regression analysis was used to determine the slope, which corresponds to the amplification efficiency. A slope value of about −3.2 with R 2 ≥ 0.99 suggested a reaction efficiency of 100% (Fig. 4B ).
The distribution of myosin-IIB protein was also analyzed by immunohistochemistry (Fig. 5) . In the cerebral cortex, myosin-IIB immunoreactivity was observed mainly in pyramidal neurons that are known to be projecting neurons. The neuronal and glial cells of the frontal and temporal cortex exhibited increased immunostaining for myosin-IIB in diabetic rat brains. The distribution of myosin-IIB in other regions of the brain was the same for non-diabetic and diabetic rats. Our results are consistent with the previously reported distribution of non-muscle myosin isoforms (myosin-IIA and myosin-IIB) in normal rat brain [45] . Although the distribution of myosin-IIB is similar in brains of diabetic and non-diabetic rats, the differential staining pattern may be linked with myosin-IIB function.
Disturbances in insulin signaling appear to be the primary impairment that affects cell growth and differentiation, cellular repair mechanisms, energy metabolism, and glucose levels [46] . It has been reported that IGF-I increases the level of myosin-IIB heavy chain mRNA in skeletal muscle [47] .
Extensive evidence has confirmed that myosin-IIB plays a role in the secretory processes of a variety of cells, including mast cells [48] , natural killer cells [49] , hippocampal cells [50] , sensory neurons [51] , chromaffin cells [52] , beta cells [53] , exocrine cells [54] [55] [56] and oocytes [57] . Furthermore, this myosin is abundant in neuronal cell bodies and neurites, where it is important for growth cone motility and axon outgrowth [16, 58] .
Myosin-IIA was recently localized in mitochondria [59] , which may indicate that it plays a role during hyperglycemia. It is also possible that the expression of myosin-IIB alters due to decreased insulin levels resulting from streptozotocin-induced diabetes; if myosin-IIB overexpression is specific to this model, then inhibition should at least partly restore myosin levels in diabetes [60] .
The identification of calmodulin-binding proteins in the brain that are expressed at different levels under distinct conditions may shed light on many important biochemical pathways and aid in the discovery of novel calmodulin targets. Our study is the first to describe the expression of calmodulin-binding proteins in the non-diabetic and diabetic brain tissue through a comparative proteomic study and to examine the overexpression of non-muscle myosin heavy chain IIB in diabetic rats. This report opens up new areas of study related to the link between myosin-IIB levels in the brain and diabetes mellitus, a metabolic disorder that is associated with a wide variety of long-term complications.
